(Reuters) - Allscripts Healthcare Solutions Inc’s shares plunged 42 percent in premarket trade on Friday, after the company forecast weak full-year earnings, hurt by software development costs and weaker bookings.
On Thursday, the healthcare information technology provider reported a lower-than-expected quarterly profit and also announced the resignation of its CFO, three directors and board Chairman Phil Pead.
Citigroup analyst George Hill said the results were strongly disappointing and downgraded the company’s stock to “neutral” from “buy.”
Hill said he was most troubled by the loss of long tenured CFO Bill Davis, who had been the public face of Allscripts to investors for many years.
“We suspect CEO Glen Tullman won a power struggle at the 11th hour leading to the board departures,” Hill said.
“Too few customers are buying its products, due to lack of confidence or satisfaction,” Barclays Capital analyst Lawrence Marsh wrote in a note.
Allscripts shares were trading at $9.27 in premarket trade. They had closed at $16.02 Thursday on the Nasdaq.
Reporting by Shailesh Kuber in Bangalore; Editing by Joyjeet Das